Medexus Pharmaceuticals (MEDXF) Short Interest Ratio & Short Volume $2.02 0.00 (0.00%) As of 05/2/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartShort InterestBuy This Stock Medexus Pharmaceuticals Short Interest DataMedexus Pharmaceuticals (MEDXF) has a short interest of 9,000 shares. This marks a -58.90% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 30,704 shares to cover all short positions.Current Short Interest9,000 sharesPrevious Short Interest21,900 sharesChange Vs. Previous Month-58.90%Dollar Volume Sold Short$15,210.00Short Interest Ratio0.3 Days to CoverLast Record DateApril 15, 2025Today's Trading Volume55 sharesAverage Trading Volume30,704 sharesToday's Volume Vs. Average0% Short Selling Medexus Pharmaceuticals? Sign up to receive the latest short interest report for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMEDXF Short Interest Over TimeMEDXF Days to Cover Over TimeMEDXF Percentage of Float Shorted Over Time Medexus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20259,000 shares $15,210.00 -58.9%N/A0.3 $1.69 3/31/202521,900 shares $36,354.00 -29.6%N/A0.8 $1.66 3/15/202531,100 shares $55,047.00 +18.7%N/A1.1 $1.77 2/28/202526,200 shares $51,076.90 +37.2%N/A0.5 $1.95 2/15/202519,100 shares $41,447.00 -89.4%N/A0.3 $2.17 1/31/2025180,500 shares $480,472.95 -32.6%N/A1.3 $2.66 1/15/2025267,900 shares $819,774.00 +76.1%N/A2.8 $3.06 12/31/2024152,100 shares $367,321.50 -3.9%N/A8.2 $2.42 12/15/2024158,200 shares $321,304.20 -23.8%N/A7 $2.03 11/30/2024207,700 shares $396,707.00 +133.4%N/A13.9 $1.91 Get the Latest News and Ratings for MEDXF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/202489,000 shares $136,170.00 +16.6%N/A2.9 $1.53 10/31/202476,300 shares $130,015.20 -16.7%N/A11.9 $1.70 10/15/202491,600 shares $171,292.00 -20.4%N/A6.6 $1.87 9/30/2024115,000 shares $224,250.00 -14.8%N/A6.8 $1.95 9/15/2024134,900 shares $269,800.00 +4.3%N/A6.4 $2.00 8/31/2024129,400 shares $235,508.00 -12.1%N/A10.7 $1.82 8/15/2024147,200 shares $262,016.00 -7.6%N/A6.5 $1.78 7/31/2024159,300 shares $275,589.00 +10.1%N/A9.2 $1.73 7/15/2024144,700 shares $250,909.80 -8.2%N/A4 $1.73 6/30/2024157,600 shares $209,608.00 -3.0%N/A10 $1.33 6/15/2024162,500 shares $185,656.25 +0.8%N/A2.2 $1.14 5/31/2024161,200 shares $188,604.00 +6.5%N/A9.8 $1.17 5/15/2024151,400 shares $180,166.00 +26.9%N/A11.4 $1.19 4/30/2024119,300 shares $160,458.50 +15.2%N/A4.1 $1.35 4/15/2024103,600 shares $118,259.40 +30.5%N/A2.4 $1.14 3/31/202479,400 shares $96,788.60 +14.6%N/A3.1 $1.22 3/15/202469,300 shares $81,081.00 +56.8%N/A2.8 $1.17 2/29/202444,200 shares $58,286.54 +122.1%N/A2.1 $1.32 2/15/202419,900 shares $27,462.00 +192.7%N/A0.3 $1.38 1/15/20247,800 shares $15,522.00 +333.3%N/A0.2 $1.99 12/31/20231,800 shares $3,402.00 No ChangeN/A0.1 $1.89 11/30/20234,200 shares $4,552.80 +35.5%N/A0.4 $1.08 11/15/20233,100 shares $4,092.00 -67.4%N/A0.3 $1.32 10/31/20239,500 shares $13,965.00 -84.3%N/A0.9 $1.47 10/15/202360,300 shares $108,540.00 -92.6%N/A6.8 $1.80 9/30/2023814,300 shares $1.82 million -5.6%N/A63.6 $2.24 9/15/2023863,000 shares $2.06 million -6.7%N/A65.9 $2.39 8/31/2023925,000 shares $2.00 million +97.5%N/A24.8 $2.16 8/15/2023468,300 shares $894,453.00 -1.2%N/A8.4 $1.91 7/31/2023474,200 shares $751,607.00 -0.3%N/A46.5 $1.59Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/15/2023475,600 shares $731,472.80 +16.2%N/A23 $1.54 6/30/2023409,300 shares $568,927.00 +0.4%N/A11.2 $1.39 6/15/2023407,600 shares $362,111.84 -0.6%N/A64.7 $0.89 5/31/2023410,000 shares $378,020.00 -0.1%N/A64.1 $0.92 5/15/2023410,200 shares $370,369.58 -1.3%N/A26 $0.90 4/30/2023415,500 shares $400,001.85 +1.8%N/A62 $0.96 4/15/2023408,200 shares $449,020.00 -1.0%N/A14 $1.10 3/31/2023412,200 shares $491,466.06 -0.9%N/A19.8 $1.19 3/15/2023415,800 shares $469,854.00 +2.0%N/A80 $1.13 2/28/2023407,600 shares $538,032.00 0.0%N/A10.1 $1.32 2/15/2023407,700 shares $387,315.00 +0.0%N/A14.2 $0.95 1/31/2023407,600 shares $574,716.00 -0.5%N/A10.3 $1.41 1/15/2023409,800 shares $649,533.00 +4.4%N/A9.9 $1.59 12/30/2022392,600 shares $604,604.00 -1.3%N/A14.5 $1.54 12/15/2022397,700 shares $562,586.42 +0.1%N/A12.5 $1.41 11/30/2022397,500 shares $680,758.50 +11.2%N/A19.1 $1.71 11/15/2022357,500 shares $493,350.00 +0.3%N/A9.3 $1.38 10/31/2022356,300 shares $381,241.00 +2.6%N/A15.6 $1.07 10/15/2022347,300 shares $309,097.00 +37.3%N/A7.1 $0.89 9/30/2022253,000 shares $179,655.30 +41.7%N/A2.3 $0.71 9/15/2022178,500 shares $255,255.00 -4.6%N/A12.4 $1.43 8/31/2022187,100 shares $357,361.00 +298.1%N/A8.5 $1.91 8/15/202247,000 shares $114,680.00 -23.1%N/A1.8 $2.44 7/31/202261,100 shares $109,980.00 -17.4%N/A5.4 $1.80 7/15/202274,000 shares $101,594.60 -15.7%N/A9.6 $1.37 6/30/202287,800 shares $135,212.00 -3.4%N/A9.4 $1.54 6/15/202290,900 shares $136,386.36 -16.6%N/A23.3 $1.50 5/31/2022109,000 shares $182,030.00 +6.2%N/A4.7 $1.67 5/15/2022102,600 shares $218,025.00 -2.1%N/A13.5 $2.13 4/30/2022104,800 shares $247,852.00 -0.9%N/A36.1 $2.37 4/15/2022105,700 shares $270,592.00 -2.3%N/A13.2 $2.56 3/31/2022108,200 shares $271,582.00 -8.0%N/A12 $2.51 3/15/2022117,600 shares $277,100.88 -11.0%N/A13.1 $2.36 2/28/2022132,100 shares $344,781.00 -3.4%N/A6.6 $2.61 2/15/2022136,700 shares $358,154.00 -7.5%N/A8.5 $2.62 1/31/2022147,700 shares $336,756.00 +0.5%N/A6.2 $2.28 1/15/2022147,000 shares $313,110.00 +6.6%N/A7.4 $2.13 12/31/2021137,900 shares $277,179.00 -4.2%N/A3.5 $2.01 12/15/2021143,900 shares $274,849.00 +38.6%N/A3.1 $1.91 11/30/2021103,800 shares $223,170.00 +84.0%N/A2.4 $2.15 11/15/202156,400 shares $133,386.00 +35.6%N/A1.5 $2.37 10/29/202141,600 shares $110,240.00 +112.2%N/A1.7 $2.65 10/15/202119,600 shares $55,693.40 +78.2%N/A0.7 $2.84 9/30/202111,000 shares $26,015.00 No ChangeN/A0.5 $2.37 8/31/20215,700 shares $18,810.00 +90.0%N/A0.1 $3.30 8/13/20213,000 shares $9,600.00 +500.0%N/A0 $3.20 7/30/2021500 shares $2,942.50 -54.6%N/A0 $5.89 7/15/20211,100 shares $6,644.00 +175.0%N/A0 $6.04 6/30/2021400 shares $2,368.00 -75.0%N/A0 $5.92 6/15/20211,600 shares $10,568.16 +100.0%N/A0 $6.61Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 5/28/2021800 shares $4,848.00 -11.1%N/A0 $6.06 5/14/2021900 shares $5,178.60 -52.6%N/A0 $5.75 4/30/20211,900 shares $11,685.00 +171.4%N/A0 $6.15 4/15/2021700 shares $4,102.70 -12.5%N/A0 $5.86 3/31/2021800 shares $5,058.56 -66.7%N/A0 $6.32 3/15/20212,400 shares $13,920.00 -96.8%N/A0 $5.80 2/26/202175,300 shares $463,848.00 -1.4%N/A1.5 $6.16 2/12/202176,400 shares $0.00 +159.9%N/A3 $0.00 1/29/202129,400 shares $0.00 +988.9%N/A0.5 $0.00 1/15/20216,300 shares $0.00 +530.0%N/A0.3 $0.00 12/31/20203,300 shares $0.00 -47.6%N/A0.3 $0.00 MEDXF Short Interest - Frequently Asked Questions What is Medexus Pharmaceuticals' current short interest? Short interest is the volume of Medexus Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 9,000 shares of MEDXF short. Learn More on Medexus Pharmaceuticals' current short interest. Is Medexus Pharmaceuticals' short interest increasing or decreasing? Medexus Pharmaceuticals saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 9,000 shares, a decrease of 58.9% from the previous total of 21,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Medexus Pharmaceuticals stock? Short selling MEDXF is an investing strategy that aims to generate trading profit from Medexus Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Medexus Pharmaceuticals? A short squeeze for Medexus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MEDXF, which in turn drives the price of the stock up even further. How often is Medexus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MEDXF, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies TGIFF Short Squeeze CATV Short Squeeze FFNTF Short Squeeze ABSCF Short Squeeze ACRHF Short Squeeze ACRDF Short Squeeze ALEAF Short Squeeze LBTSF Short Squeeze ALVOW Short Squeeze ERBB Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:MEDXF) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MEDXF Stock Free MEDXF Stock Alerts